Zero Incidence of Inhibitors in Previously Untreated Patients who Received Intermediate Purity Factor VIII Concentrate or Factor IX Complex

References
1 Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs: A review of the literature. Blood Coagul Fibrinolysis 1993; 4: 753-758
2 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A NEJM 1993; 328: 453-459
3 Bray GL, Gomperts ED, Courier S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White III G, Lee M. and the Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435
4 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao V, Lazerson Jand. The Hemophilia Study Group. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII.C inhibitors. Blood 1988; 71: 344-348
5 Sharpiro A, Abe T, Aledort LM, Anderle K, Hilgartner MW, Kunschak M, Preston FE, Rivard GE, Schimpf K. The International Factor Study Group. Low risk of viral infection after administration of vapor-heated Factor VII Concentrate or Factor IX Complex in first-time recipients of blood products. Transfusion 1995; 35
6 Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PB A, Kunschak M, McMillan CW, Preston FE, Rivard GE. The International Investigator Group. Low risk of viral infection after administration of vapor-heated factor VIII concentrate Transfusion 1992; 32: 134
7 Goldsmith JC. Diagnosis of factor VIII versus nonspecific inhibitors. Semin Hematol 199 30 (02) Suppl (Suppl. 01) 3-6
8 Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung RRocino, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A: a meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. (Letter to the Editor) Thromb Haemost 1994; 72: 162-163